The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial comparing IG-001 versus paclitaxel against first-line advanced ovarian cancer.
Vuong N. Trieu
Employment or Leadership Position - Sorrento Therapeutics
Stock Ownership - Sorrento Therapeutics
Research Funding - Sorrento Therapeutics
Monica Choi
Employment or Leadership Position - Sorrento Therapeutics
Stock Ownership - Sorrento Therapeutics
Research Funding - Sorrento Therapeutics
Larn Hwang
Employment or Leadership Position - Sorrento Therapeutics
Stock Ownership - Sorrento Therapeutics
Research Funding - Sorrento Therapeutics
Osmond D'Cruz
Employment or Leadership Position - Sorrento Therapeutics
Stock Ownership - Sorrento Therapeutics
Research Funding - Sorrento Therapeutics